Abstract
Purpose
The aim of this study was to analyze the detection rate for CRC and adenomas for asymptomatic subjects in Japan by FDG-PET cancer screening program carried out between 2006 and 2009.
Methods
The “FDG-PET cancer screening program” included both PET and positron emission tomography with computed tomography (PET/CT) with or without other screening tests. A total of 154,783 asymptomatic subjects underwent FDG-PET cancer screening program; we analyzed the 1,808 cases with findings from any detection method that indicated suspected CRC.
Results
Among the 1,808 cases, the number of cases verified as CRC and adenoma was 394 and 679, respectively. The sensitivity and positive predictive value (PPV) of FDG-PET were 86.0 and 31.7 % for CRC, and 63.6 and 63.8 % for CRC and adenoma. The sensitivity and PPV of fecal occult blood test (FOBT) for CRC were lower than those of FDG-PET, but higher for adenoma. Therefore, FDG-PET and FOBT were complementary for screening for CRC, and CRC and adenoma. The majority of CRC detected by the FDG-PET imaging was UICC stage 0 or I, however, detection of smaller or less invasive cancer was limited.
Conclusion
The FDG-PET screening program in Japan has detected CRC at an early stage and adenomas as premalignant lesions. A combination of FDG-PET and FOBT yields the best results if the intent is to detect either CRC or adenoma. However, it is absolutely clear that an FDG-PET cancer screening program cannot detect all colon lesions.
Similar content being viewed by others
References
National Cancer Institute. Cancer screening overview (PDQ). http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional#Section_2.
Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol. 2005;23:293–300.
National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection.
Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med. 2007;48(Suppl 1):4S–18S.
Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. Radiographics. 2007;27:145–59.
Minamimoto R, Senda M, Jinnouchi S, et al. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey. Ann Nucl Med. 2013;27:46–57.
The guideline of FDG-PET cancer screening. 2004. http://www.jst.go.jp/keytech/01bunshi/fdg.pdf.
The guideline of FDG-PET cancer screening. Kaku Igaku. 2007; 44:1–28.
Chen YK, Ding HJ, Su CT, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res. 2004;24:4103–8.
Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging. 2006;50:23–7.
Minamimoto R, Senda M, Uno K, et al. Performance profile of FDGPET and PET/CT for cancer screening on the basis of a Japanese nationwide survey. Ann Nucl Med. 2007;21:481–98.
Minamimoto R, Senda M, Terauchi T, et al. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann Nucl Med. 2011;25:45–54.
Ono K, Ochiai R, Yoshida T, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med. 2007;21:65–72.
Ko DH, Choi JY, Song Y, et al. The usefulness of 18F-FDG PET as a cancer screening test. Nucl Med Mol Imaging. 2008;42:444–50.
Kojima S, Zhou B, Teramukai S, et al. Cancer screening of healthy volunteers using whole-body 18F-FDGPET scans: the Nishidai clinic study. Eur J Cancer. 2007;43:1842–8.
Nishizawa S, Kojima S, Teramukai S, et al. Prospective evaluation of wholebody cancer screening with multiple modalities including [18F] fluorodeoxyglucose positron emission tomography in a healthy population: preliminary report. J Clin Oncol. 2009;27:3–1767.
Lee JW, Kang KW, Paeng JC, et al. Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med. 2009;23:685–91.
Svensson MH, Svensson E, Lasson A, Hellström M. Patient acceptance of CT colonography and conventional colonoscopy: prospective comparative study in patients with or suspected of having colorectal disease. Radiology. 2002;222:337–45.
Edwards JT, Mendelson RM, Fritschi L, et al. Colorectal neoplasia screening with CT colonography in average-risk asymptomatic subjects: community-based study. Radiology. 2004;230:459–64.
van Gelder RE, Birnie E, Florie J, et al. CT colonography and colonoscopy: assessment of patient preference in a 5-week follow-up study. Radiology. 2004;233:328–37.
Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849–57.
Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res. 2003;23:4357–61.
Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46:752–7.
Luboldt W, Volker T, Wiedemann B, et al. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardized PET cut-off. Eur Radiol. 2010;20:2274–85.
Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–62.
Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol. 2005;185:495–500.
Nakajo M, Jinnouchi S, Tashiro Y, et al. Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET. AJR Am J Roentgenol. 2009;192:754–60.
Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002;224:783–7.
Minamimoto R, Terauchi T, Jinnouchi S, et al. Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake. Ann Nucl Med. 2013;27:468–77.
Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:3053–63.
Chen CD, Yen MF, Wang WM, Wong JM, Chen TH. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer. 2003;88:1866–73.
Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977–81.
Read TE, Read JD, Butterly LF. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl J Med. 1997;336:8–12.
Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343:162–8.
Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med. 2003;349:2191–200.
Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989–92.
Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-) malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med. 2001;28:1766–9.
Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology. 2004;230:417–22.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541–9.
Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.
Hundt S, Haug U, Brenner H. (2009) Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150:162–9.
van Kouwen MC, Nagengast FM, Jansen JB, Oyen WJ, Drenth JP. 2-(18F)-Fluoro-2-deoxy-d-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol. 2005;23:3713–7.
Hirakawa T, Kato J, Okumura Y, et al. Detectability of colorectal neoplasia with fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT). Gastroenterol. 2012;47:127–35.
Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.
Terauchi T, Murano T, Daisaki H, et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008;22:379–85.
The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann. ICRP 2007;37(2–4).
Murano T, Minamimoto R, Senda M, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nation-wide survey. Ann Nucl Med. 2011;25:657–66.
Acknowledgments
This work was supported by the National Cancer Center Research and Development Fund 23-A-25, Japanese Council of PET Imaging: working group on epidemiology study for PET cancer screening, the PET cancer screening research group of Yokohama City University. The authors would like to express our sincere appreciation and gratitude to Sachiko Yanagida and Yoshihide Nakamura from Japan Radioisotope Association for management of this survey.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Minamimoto, R., Senda, M., Jinnouchi, S. et al. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey. Ann Nucl Med 28, 212–219 (2014). https://doi.org/10.1007/s12149-013-0797-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-013-0797-2